{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:54:01Z","timestamp":1778864041392,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Childhood acute myeloid leukemia (AML) requires intensive chemotherapy, which may result in life-threatening bloodstream infections (BSIs). This study evaluated whether machine learning (ML) could predict BSI using electronic medical records. All children treated for AML at Children\u2019s Minnesota between 2005 and 2019 were included. Patients with Down syndrome AML or acute promyelocytic leukemia were excluded. Standard statistics analyzed predictors of BSI, and ML models were trained to predict BSI. Of 95 AML patients, 54.7% had BSI. Of 480 admissions, 19% included BSI. No deaths were related to BSI, and survival of non-Whites was significantly inferior to White patients. Logistic regression revealed that higher cytarabine doses increased the risk of BSI, with an odds ratio (OR) of 1.110 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). Prophylactic levofloxacin-vancomycin reduced the risk of BSI, with OR of 0.495 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). The best-performing ML model was regularized logistic regression with an area under the curve (AUC) of 0.748, improved specificity by 37.5% compared with neutropenia, and 2.6% compared with fever. In conclusion, BSI risk was increased by cytarabine and reduced by levofloxacin-vancomycin prophylaxis. ML predicted BSI with improvement over fever or neutropenia. In clinical practice, ML may offer flexibility by controlling sensitivity and specificity by adjusting BSI diagnosis thresholds.<\/jats:p>","DOI":"10.1097\/mph.0000000000002957","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T16:01:11Z","timestamp":1731340871000},"page":"e26-e33","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Bloodstream Infections in Childhood Acute Myeloid Leukemia and Machine Learning Models: A Single-institutional Analysis"],"prefix":"10.1097","volume":"47","author":[{"given":"Taylor L.","family":"Chappell","sequence":"first","affiliation":[{"name":"Department of Industrial and Systems Engineering, University of Wisconsin-Madison"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen G.","family":"Pflaster","sequence":"additional","affiliation":[{"name":"Department of Industrial and Systems Engineering, University of Wisconsin-Madison"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Resty","family":"Namata","sequence":"additional","affiliation":[{"name":"Health Information Services, Children\u2019s Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jometa","family":"Bell","sequence":"additional","affiliation":[{"name":"Health Information Services, Children\u2019s Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lane H.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Children\u2019s Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Pomputius","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, Children\u2019s Minnesota, Minneapolis, Minnesota, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin J.","family":"Boutilier","sequence":"additional","affiliation":[{"name":"Department of Industrial and Systems Engineering, University of Wisconsin-Madison"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7990-1802","authenticated-orcid":false,"given":"Yoav H.","family":"Messinger","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Children\u2019s Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"R1-20241231","doi-asserted-by":"crossref","first-page":"e26300","DOI":"10.1002\/pbc.26300","article-title":"Risk factors for and prevention of bloodstream infection in pediatric AML\u2014the debate continues","volume":"64","author":"Simon","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"R2-20241231","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/cncr.24107","article-title":"Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia.","volume":"115","author":"Sung","year":"2009","journal-title":"Cancer"},{"key":"R3-20241231","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2007-05-091942","article-title":"Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia","volume":"110","author":"Sung","year":"2007","journal-title":"Blood"},{"key":"R4-20241231","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1200\/JCO.2000.18.9.1845","article-title":"Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children\u2019s cancer group study CCG-2891","volume":"18","author":"Gamis","year":"2000","journal-title":"J Clin Oncol"},{"key":"R5-20241231","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/INF.0000000000000058","article-title":"Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group","volume":"33","author":"Lewis","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20241231","doi-asserted-by":"crossref","first-page":"e26254","DOI":"10.1002\/pbc.26254","article-title":"Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: a single-institution report","volume":"64","author":"Rogers","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20241231","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial","volume":"320","author":"Alexander","year":"2018","journal-title":"JAMA"},{"key":"R8-20241231","doi-asserted-by":"crossref","first-page":"e28469","DOI":"10.1002\/pbc.28469","article-title":"Cost-effectiveness of levofloxacin prophylaxis against bacterial infection in pediatric patients with acute myeloid leukemia","volume":"67","author":"McCormick","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"R9-20241231","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00277-016-2833-5","article-title":"Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia.","volume":"96","author":"Boztug","year":"2017","journal-title":"Ann Hematol"},{"key":"R10-20241231","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.28688","article-title":"Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia","volume":"120","author":"Inaba","year":"2014","journal-title":"Cancer"},{"key":"R11-20241231","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cncr.23563","article-title":"Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia","volume":"113","author":"Kurt","year":"2008","journal-title":"Cancer"},{"key":"R12-20241231","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/pbc.25463","article-title":"Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML)","volume":"62","author":"Nolt","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20241231","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MPH.0b013e318257a6ca","article-title":"Vancomycin-resistant Enterococcus in pediatric oncology patients: balancing infection prevention and family-centered care","volume":"35","author":"Singh","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"R14-20241231","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","article-title":"Outcomes in CCG-2961, a children\u2019s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children\u2019s oncology group","volume":"111","author":"Lange","year":"2008","journal-title":"Blood"},{"key":"R15-20241231","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"key":"R16-20241231","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"key":"R17-20241231","doi-asserted-by":"crossref","first-page":"1286241","DOI":"10.3389\/fcvm.2023.1286241","article-title":"Rationale and design of the Children\u2019s Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy","volume":"10","author":"Leger","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R18-20241231","first-page":"123","article-title":"Significance Tests For 2\u00d72 Tables","volume":"34","author":"Barnard","year":"1947","journal-title":"Biometrika"},{"key":"R19-20241231","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"R20-20241231","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.3747\/co.26.5625","article-title":"Role of real-world evidence in informing cancer care: lessons from colorectal cancer","volume":"26","author":"Batra","year":"2019","journal-title":"Curr Oncol"},{"key":"R21-20241231","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/bloodadvances.2021004735","article-title":"Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia","volume":"5","author":"Conneely","year":"2021","journal-title":"Blood Adv"},{"key":"R22-20241231","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1182\/bloodadvances.2022007544","article-title":"High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML","volume":"6","author":"Larkin","year":"2022","journal-title":"Blood Adv"},{"key":"R23-20241231","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ajh.24605","article-title":"The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia","volume":"92","author":"Winestone","year":"2017","journal-title":"Am J Hematol"},{"key":"R24-20241231","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/BF01743253","article-title":"High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia","volume":"65","author":"Kern","year":"1987","journal-title":"Klin Wochenschr"},{"key":"R25-20241231","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/pbc.24448","article-title":"High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine","volume":"60","author":"Johannsen","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R26-20241231","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/cid\/ciz1082","article-title":"Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation","volume":"71","author":"Lehrnbecher","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R27-20241231","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(20)30725-7","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Lehrnbecher","year":"2021","journal-title":"Lancet Oncol"},{"key":"R28-20241231","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1086\/340352","article-title":"Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis","volume":"34","author":"Razonable","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R29-20241231","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1186\/s12885-020-07618-2","article-title":"Development and utility assessment of a machine learning bloodstream infection classifier in pediatric patients receiving cancer treatments","volume":"20","author":"Sung","year":"2020","journal-title":"BMC Cancer"},{"key":"R30-20241231","doi-asserted-by":"crossref","first-page":"e27978","DOI":"10.1002\/pbc.27978","article-title":"Outcomes after bloodstream infection in hospitalized pediatric hematology\/oncology and stem cell transplant patients","volume":"66","author":"Dandoy","year":"2019","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:20:19Z","timestamp":1735658419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002957","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"2024-03-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}